ORGS

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q1 2021 Results - Earnings Call Transcript

ORGS Stock: Over 10% Increase Intraday Explanation

Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy

ORGS Stock: 14.06% Increase Pre-Market (From $4.48 To $5.11) Explanation

Orgenesis reaches milestone with US FDA approval of Tissue Genesis Icellator2 pilot trial

Orgenesis to collaborate with Bambino Gesù Children's Hospital in Rome on new therapy centre

Orgenesis to collaboration with Bambino Gesù Children's Hospital in Rome on new therapy centre